|
Abstract
&
Speaker Information
The abstract submission
site is closed. Notification of abstract selection will
be e-mailed to submitting authors and will be available
on this Web site beginning December 19, 2005. All accepted
abstracts will be published in a 2006 supplement(s)
to the Journal of the American College of Cardiology.
All authors must comply with the
ACC embargo policy, which states that scientific study
results to be presented during the Annual Scientific
Session must not be revealed to the public prior to
the scheduled time of presentation at ACC.06/i2 Summit
2006 or the ACC news conference, whichever one comes
first.
Topic areas relating to the
i2 Summit 2006 meeting include:
- Angiography and QCA
- Atherectomy (excluding thrombectomy)
- Atrial Fibrillation Therapies
- Intravascular Diagnostics: Ultrasound/Angioscopy/Vulnerable
Plaque/Others
- Medical Simulation
- Miscellaneous Interventional Topics:
Outcomes/Operator Volume/Public Reporting/Misc
- CTA/MRI In and Out of the Cath
Lab
- Percutaneous Interventions-- Pharmacologic/Biologic
Adjuncts
- Percutaneous Interventions--ACS/Non-STEMI
- Percutaneous Interventions—Acute
and Chronic Renal Insufficiency
- Percutaneous Interventions--Acute
Myocardial Infarction
- Percutaneous Interventions--Angiogenesis,
Myogenesis, Gene and Cell Therapies
- Percutaneous Interventions--Bifurcations
- Percutaneous Interventions--Chronic
Total Occlusions
- Percutaneous Interventions--Congenital/Structural
& HCM
- Percutaneous Interventions--Diabetes
- Percutaneous Interventions--Drug
Eluting Stents
- Percutaneous Interventions--Left
Main Disease
- Percutaneous Interventions--Neurovascular,
Carotid and Stroke Intervention
- Percutaneous Interventions--Thrombectomy/SVG/Embolic
Protection
- Percutaneous Interventions--Valvular
- Pharmacotherapy--Interventional
(UFH, LMWH and Direct Thrombin Inhibitors and pre
or post procedure)
- Restenosis and In-Stent Restenosis--Prevention
and Management
- Restenosis--Basic Research
- Vascular Access, Closure
Devices and Complications
Topic areas relating to the ACC.06
meeting include:
- Myocardial Ischemia and Infarction;
- Vascular Disease, Hypertension
and Prevention;
- Valvular Heart Disease;
- Cardiac Function and Heart Failure;
- Cardiac Arrhythmias;
- Imaging and Diagnostic Testing;
- Pediatric Cardiology and Adult
Congenital Heart Disease; and
- Special Topics.
For a further
breakdown of abstract categories in the topic areas
listed above, click
here.
New for ACC.06:
The College has added a brand new abstract submission
category, Innovative Models for Practice, Education
or Research. Priority will be given to submission
that demonstrate a team-based approach to cardiac care
or include nonphysician professionals.
Questions? Call the Resource Center
at: 800-253-4636, ext. 694 (outside the United States
and Canada, 301-897-2694).
Abstract Presenter Registration
Accepted abstract presenters may register beginning
Dec. 19, 2005, as a Scientific Session Abstract Presenter,
and will be charged a $75 meeting registration fee.
Abstract submitters who wish to register and secure
housing before abstract notification should register
in the appropriate category (member, nonmember, etc.)
and then request a refund of overpaid fees if an abstract
is accepted.
All presenters must complete a registration
form to obtain a hotel reservation and meeting badge.
Registration and housing opens for ACC members on September
15, 2005. General registration opens on September 29,
2005.
Late-Breaking
Clinical Trials
Deadline for LBCT submission: Thursday,
January 5, 2006, 11:59 p.m. Central Standard Time (CST);
online submission process only.
The Annual Scientific Session Program Committee and
the i2 Summit Steering Committee invites you to submit
applications of late-breaking clinical trial research
for consideration in the 55th Annual Scientific Session.
New this year: There will be several
types of Late-Breaking Clinical Trial sessions and the
opportunity for early acceptance. Late-Breaking Clinical
Trials submissions will undergo a peer-review process
leading to selection for presentation. These sessions
provide significant exposure and recognition for major
studies likely to affect clinical practice in an important
way.
In addition to the traditional Late-Breaking Clinical
Trials, the Program Committee wants to feature smaller
studies that have examined novel therapies or innovative
technologies in a randomized clinical trial setting.
The submission site will also be open to hypothesis-generating,
cutting edge research with smaller enrollments and to
entries that present newsworthy information from large,
multi-center observational studies. Potential presenters
must complete an online application outlining the purpose,
design, and methods of the study. Evaluation for presentation
in the Late-Breaking Clinical Trial sessions will be
based on the potential clinical significance and impact
as well as the novelty of the research; rigor of the
design and methods; major clinical endpoints; and the
quality of the statistical plan. Priority will be given
to trials whose results will be publicly presented for
the first time at ACC.06 and i2 Summit 2006.
For early acceptance for key late-breaking clinical
trials, the application must be submitted by Dec. 5,
2005. Early acceptance notification will be provided
by Dec. 14, 2005. All other submissions will be considered
after the Late-Breaking Clinical Trials submission site
closes on Jan. 5, 2006. Notification of all acceptances
will be provided the week of Jan. 30, 2006.
General Information
- These sessions provide notable
exposure and recognition for studies likely to affect
clinical practice significantly. Potential presenters
must complete an online application outlining the
purpose, design, and methods of the study. Evaluation
for presentation in the Late-Breaking Clinical Trial
sessions will be based on the impact and novelty of
the research; rigor of the design/methods; major clinical
endpoints; and the quality of the statistical plan.
Priority will be given to trials whose results will
be presented for the first time at ACC.06 and i2 Summit
2006.
- Investigators need not be ACC
members to participate.
- There is a $100 non-refundable
processing fee for each LBCT application submitted
payable online by credit card only.
- The College is unable to reimburse
Annual Scientific Session and i2 Summit faculty for
travel, hotel, and per diem expenses. The registration
fee is waived for accepted LBCT presenters; however,
a registration form must be completed to obtain a
hotel reservation and meeting badge. If you have not
already registered, please contact Meeting Services
for a copy of the form: by e-mail presenters@acc.org
or i2presenters@acc.org;
by telephone 800-253-4636, ext. 663, or 301-897-2663
outside of North America; or fax 301-897-9745. Return
the form by fax to I.T.S., (800-521-6017) the ACC
official registration and housing bureau. If you have
already registered and paid the registration fee,
please request a refund in writing, attention Meeting
Services ACC.06 Registrar, fax 301-897-9745.
- Notification will be sent to the
person who submitted the application with final disposition
information during the week of Jan. 30, 2006.
- General information subject to
change due to circumstances beyond the ACC’s
control.
Policies
1. Applications must be SUBMITTED
BY 11:59 p.m. CENTRAL STANDARD TIME ON THURSDAY, JANUARY
5, 2006. The American College of Cardiology is not responsible
for submissions, which are not submitted by this deadline
date.
2. Submissions with system status
of “incomplete” cannot be processed.
3. Submission of an application constitutes a commitment
by the author(s) to present if accepted. Failure to
present and register for the meeting, if not justified,
will jeopardize future acceptance of applications.
4. There is no limit to the
number of applications an investigator may submit. If
selected, the presenter must be one of the co-authors
listed.
5. Investigators should not
submit the same research; applications that appear to
be replicate versions of a single study will be rejected.
6. Follow all instructions for
completing the submission. Be sure to structure the
content into Background, Methods, Results, and Conclusion
(if known) sections.
7. Clarity of expression will
be considered in the review process. The overall quality
of language used should assure comprehension by the
reader.
8. Use a maximum of five unique
abbreviations in the body of the application. No abbreviations
should appear in the title. Place abbreviations in parentheses
after the full word the first time it appears. Abbreviations
increase the difficulty of reading and evaluating applications,
which will be considered in the review process.
9. If authors' names appear
on more than one application, their names must appear
and be spelled identically on each application in order
to facilitate proper indexing. Whenever possible, do
not list authors with initials only.
10. Any abstract presenting
data that in whole or part is contained in a Late-Breaking
Clinical Trial submission that was submitted in October
for presentation in the general program cannot be presented
in the regular program and must be withdrawn if that
trial is accepted for presentation as a Late-Breaking
Trial. Please notify Dianne J. Lee (301-897-2667 or
djlee@acc.org) if another abstract based on the clinical
trial was submitted via the regular abstract submission
process.
11. Submitters may return to
the online system to edit applications, revise information,
correct typographical errors, tables, graphics, or delete
a submission at any time before 11:59 p.m. Central Time
on January 5, 2006. After this time, the system will
be closed, and submissions will be forwarded for the
reviewing process. An author may not revise or resubmit
an application in order to make changes or corrections
after this deadline. Proofread applications carefully
to avoid errors before they are submitted. ACC is not
authorized to make changes to a submission. This includes
typographical errors. If you choose to withdraw an application
after the submission deadline, this request must be
received by ACC in writing. Please notify Dianne J.
Lee (301-897-2667 or djlee@acc.org)
12. Applications are not eligible
for consideration if the data have been presented at
a U.S. or international meeting held before the ACC
Annual Scientific Session.
13. Applications are not eligible
for consideration if the data have been published before
the ACC Annual Scientific Session.
14. Any human experimentation
must conform to the principles of the Declaration of
Helsinki of the World Medical Association.
15. The Annual Scientific Session
Program Committee and the i2 Summit Steering Committee
endorse the position of the American Association for
the Advancement for Science in requiring assurances
of the responsible use of animals in research. All submissions
for consideration must be in compliance with the guidelines.
16. Each presenting author will
be asked to comply with the ACCF “Statement of
Disclosure (Vested Interest) and Conflict of Interest
for Accredited Educational Activities” Policy.
Indication of the relationship, the associated commercial
entity and level of support is required for each author
at the time of submission. Again this year, all presenters
at ACC.06 and i2 Summit 2006 must display a slide (or
equivalent if poster session) at the beginning of their
presentation indicating disclosure information as applicable,
or that they have nothing to disclose.
17. The submitter acts on behalf
of all co-authors and in submitting an application,
transfers to the American College of Cardiology the
copyright and all other rights in the material comprising
the application if the application is accepted. Co-authors
reserve the following: a) all proprietary rights other
than copyright, such as patent rights; and b) the right
to use all or part of the application in future works
of their own. The American College of Cardiology, as
holder of the copyright on the accepted application,
reserves all rights of reproduction, distribution, performance,
display, and the right to create derivative works in
both print and digital formats.
18. In light of increased attention
to the manner in which research results (particularly
those affecting the stock of publicly-traded companies)
are made public, ACC is clarifying its policies and
procedures regarding disclosure of applications. All
applications submitted are disclosed to members of the
peer review selection committee, as well as to ACC employees
and contractors as necessary in connection with the
annual meeting. Those applications that are accepted
for presentation are summarized for publication after
the Annual Scientific Session and are not publicly available
to the public in advance of the annual meeting. The
usual procedures for summarizing presentations are set
forth below under “Accepted Submissions.”
Applications not accepted for presentation are not summarized,
and are ordinarily not disclosed outside of ACC and
persons associated with the selection process (i.e.,
the peer review committee). Notwithstanding these policies
and procedures, ACC is not subject to any confidentiality
requirements with respect to submitted applications.
In addition, compliance with any disclosure or nondisclosure
requirements that apply to researchers or research sponsors
(whether under federal securities laws, contract agreement,
or otherwise) is the sole responsibility of the researcher
and/or sponsor, and not the ACC.
19. Clinical trial results are
embargoed from being presented or announced in any forum
until the time of the presentation. This includes presentations
at satellite meetings or press conferences held before
the scheduled Annual Scientific Session/i2 Summit trial
presentation. Clinical trial sponsors must comply with
embargo guidelines. Trials which ignore the embargo
rules run the risk of being withdrawn from the program
on-site. Failure of investigators or sponsors to honor
this embargo will jeopardize future acceptance of clinical
trials by the sponsor, or presentations by the principal
investigator, at the annual scientific sessions of the
American College of Cardiology (ACC), American Heart
Association (AHA), and the European Society of Cardiology
(ESC) for a period of two (2) years.
20. Investigator meetings: The
only exception to the above mentioned embargo rules
are closed investigator meetings for participants in
the trial. These meetings must be held at the Annual
Scientific Session and may be held beginning Saturday,
March 11, 2006. The Annual Scientific Session and i2
Summit Program Committees wish to be apprized of these
meetings. If your trial submission is accepted for presentation,
you will be asked to supply investigator meeting date/time/location
information with your acceptance material.
Accepted Submissions
Titles and presenters of accepted presentations will
be listed in the Final Program available on site at
the meeting. Title and presenter listings will also
be posted in the online Program Planner in mid February.
The person submitting an accepted application will receive
an e-mail during the week of Jan. 30. The submitter
will be asked to reconfirm the name and contact information
of the presenter; complete disclosure information; and
indicate audiovisual needs on the Presenter’s
Agreement.
The ACC provides an all-electronic
format for audiovisual requirements. All meeting rooms
will be networked. Presenters will be required to email
their presentation in advance; or bring their presentation
on a floppy disk or CD-Rom to the Speaker Ready Room,
where they will have the opportunity to review or make
changes on computers in the room, and then give the
okay for the presentation to be uploaded to the appropriate
meeting room. Presentations will be downloaded from
a central server and sent to the respective meeting
room on a secured site before the start of the session.
A listing of the audiovisual hardware/software
provided in each of the education rooms will be indicated
on the Presenter’s Agreement.
Click
here to enter the submission site.
|
